BrainCool AB has now delivered MiniChill to the Japanese hospital in Nagoya at the Department of Emergency and Critical Care. The deliveries relate to an animal-based clinical study focusing on selective brain cooling in a cardiac arrest model. The Japanese hospital is responsible for the costs of the study, while BrainCool receives limited revenues of approximately SEK 100,000 for the deliveries.

BrainCool will receive valuable feedback regarding the results of the study. Selective brain cooling means that the cooling is directed to certain brain regions to protect from damage during a cardiac arrest.

MiniChill is a new product developed by BrainCool and it is based on RhinoChill™ System, which is a compact and portable cooling system for fast and early cooling. Cooling occurs via the nasal cavities. The MiniChill is smaller, and the weight has been reduced from 13 kg to only 5 kilos, which facilitates transport and handling. Design and function have mainly been retained, while some electronics have been updated in the new MiniChill.
 
CEO Martin Waleij comments:
- “A positive outcome of the study will support the market approval process in Japan. In addition, it can confirm the effectiveness of the technology, which is important for building trust and spreading to the industry for rapid and early cooling treatment.”

Contacts
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se         

About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.

Attachments
BrainCool AB (publ) – delivers the new MiniChill to a Japanese clinical study